Research · Sep 3, 2026
[HSIC] Henry Schein Thesis 2026: Post-Ransomware Recovery Tests Dental Distribution Resilience
Henry Schein, Inc. (NASDAQ: HSIC) FY2025 revenue ~$13-14B (+5-7%) with adj. EPS ~$4.20-5.20 reflecting continued post-October 2024 BlackCat/ALPHV ransomware cyberattack recovery (~$300M+ revenue impact + $50-100M response costs) + selected Dental distribution leadership ($8B; ~25-30% global market share) + selected Medical cycle stabilization + selected continued ~36-year CEO continuity under Stanley Bergman (one of longest-tenured S&P 500 CEOs). Leading global dental + medical distribution + dental practice management software firm. Founded 1932 by Henry Schein in Queens New York as small dental supply company; ~93-year heritage; IPO November 1995 NASDAQ; selected post-IPO ~30x+ stock appreciation through 2024 albeit with selected post-October 2024 cyberattack volatility. Headquartered in Melville New York; ~25,000+ employees globally with ~$13-14B revenue. Three reporting segments: Dental ~60% revenue ($8B — dental supplies ~$5B+ + dental equipment ~$1.5B+ + practice management software Dentrix + Easy Dental ~$500M+ via Henry Schein Practice Solutions ~10K+ dental practices; ~250K+ dental customers globally; ~25-30% global dental distribution market share), Medical ~30% ($4B — physician office medical supplies ~$3B+ + alternate care + ambulatory surgery centers; ~150K+ medical customers), Technology + Value-Added Services ~10% ($1.3B — practice management + revenue cycle + dental laboratory). October 2024 ransomware cyberattack: October 14-15, 2024 BlackCat/ALPHV ransomware cyberattack on Henry Schein's distribution operations (selected Russia-affiliated cybercriminal group also responsible for MGM + UnitedHealth Change Healthcare attacks); ~3-4 weeks distribution operations disruption (order processing + ERP systems); ~$300M+ FY2024-2025 revenue impact (primarily Q4 2024 + Q1 2025); $50-100M response costs (forensic investigation + system rebuild + legal/regulatory). Company response: refused ransom payment + engaged Mandiant + selected forensic firms + ~$50-100M cybersecurity infrastructure rebuild + enhanced cyber resilience post-2024. CEO Stanley Bergman since 1989 (~36-year tenure; one of longest-tenured S&P 500 CEOs; CPA + Wits University South Africa Bachelor of Commerce; concurrent Chairman + CEO; ~40-year company career joining Henry Schein 1980). Selected Bergman era: ~$300M FY1990 → ~$13B+ FY2025 revenue scale (~40x growth); aggressive distribution + technology M&A; international expansion to ~32+ countries. Capital return: $0 dividend FY2025 (no dividend); modest buybacks $200-400M FY2025; investment-grade Baa2/BBB credit ratings; FCF $400-600M. FY2026 thesis: post-cyberattack revenue recovery + Dental cycle stabilization + Medical growth + Practice management software acceleration. Risks: secondary ransomware attack, major customer attrition >5%, Patterson Companies + selected dental distribution competitive intensity, major dental cycle reversal.